GeNeuro temporarily suspends MS trial, will focus on COVID-19 efforts
Category: #health  By Mateen Dalal  Date: 2020-03-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

GeNeuro temporarily suspends MS trial, will focus on COVID-19 efforts

  • The pharmaceutical firm will prioritize resources towards COVID-19 pandemic
  • Phase 2 trial in MS patients will commence once the hospitals have enough research capacity

Switzerland based biopharmaceutical firm- GeNeuro has recently announced temporary halt of its Phase 2 clinical trial of temelimab used in the treatment of multiple sclerosis, at the Karolinska Institutet’s Academic Specialist Center, Sweden, owing to the need to cater to the healthcare resource requirements to fight Coronavirus pandemic and to reduce the exposure to risk among MS patients.

According to Jesús Martin-Garcia, CEO, GeNeuro, the postponement is a necessary decision undertaken by the company to help meet the medical requirements of coronavirus and prioritize the treatment of the infected patients. The decision also aims at safeguarding the health of patients diagnosed with multiple sclerosis, he further stated.

Reportedly, the Phase 2 trial will be initiated once the hospitals have enough capacities to carry out clinical research and ensure that the patients will not be exposed to any type of risk.

For the record, the one-year clinical trial will register patients who do not witness any relapses and will document the safety and tolerability of temelimab after injecting with higher dosage, along with efficacy based on the latest biomarkers linked with disease progression.

Founded in the year 2006, GeNeuro is a clinical stage pharmaceutical headquartered in Zurich that aims at understanding and restricting the factors that drive the development of neurodegenerative and autoimmune diseases, including multiple sclerosis The company has its R&D center in Lyon, France and comprises of 23 employees and the right to over 17 patents safeguarding its technology.

Many other clinical trials and research work have been impacted owing to the COVID-19 threat globally. These include postponing of a registration study for Parkinson’s treatment, as well as separate trials of COPD, geographic atrophy, cancer treatment, among others, undertaken by several companies and in different stages of research.

Source Credits: http://www.geneuro.com/data/news/GeNeuro-PR-TemelimabCOVID19-EN.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...